The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

The Oncology Institute, Inc. (NASDAQ: TOI), a leader in value-based community oncology care, has announced the release date for its fourth quarter and full year 2025 earnings. The financial results will be disclosed on Thursday, March 12, 2026, followed by a conference call scheduled for 5:00 p.m. Eastern Time on the same day.

Investors and interested parties can access the conference call by dialing 1-877-407-0789 (for U.S. callers) or 1-201-689-8562 (for international callers). Those unable to join live will have the opportunity to listen to a replay, available two hours after the call concludes, by calling 1-844-512-2921 or 1-412-317-6671 for international access. The replay will remain accessible until March 19, 2026, with the passcode for both the live call and replay being 13758646. Additionally, a live webcast of the conference call will be available on the Investor Relations section of The Oncology Institute's website at https://investors.theoncologyinstitute.com/.

Founded in 2007, The Oncology Institute is dedicated to transforming the landscape of oncology care by providing specialized, evidence-based cancer treatments in community settings. TOI serves a diverse patient population of roughly 1.9 million, offering a range of services that include clinical trials and transfusions, akin to those found in top-tier healthcare institutions. With a team of over 180 clinicians and more than 100 clinic locations across five states, The Oncology Institute is committed to improving the standards of oncology care through innovative approaches and community-driven solutions.

For further details, media inquiries can be directed to marketing@theoncologyinstitute.com, while investors may contact ICR Healthcare at TOI@icrhealthcare.com.

The Oncology Institute, Inc. (NASDAQ: TOI) is scheduled to release its fourth quarter and full year 2025 financial results on March 12, 2026, with an accompanying conference call at 5:00 p.m. Eastern Time. This quarterly earnings announcement is pivotal for current and prospective investors, as it provides valuable insights into the company’s financial health and operational effectiveness within the rapidly evolving oncology care market.

As a leader in value-based community oncology care, TOI's financial disclosure will illuminate key metrics such as revenue growth, patient volume increases, and advancements in clinical trial participation. Investors should closely monitor these figures to assess TOI’s scalability and market penetration strategies. Given that TOI serves approximately 1.9 million patients across multiple states with over 100 clinics, signs of robust growth or patient retention may bolster investor confidence.

The conference call will offer a platform for TOI's leadership to discuss not only the financial results but also the strategic initiatives and innovations in cancer care that the company is pursuing. Analysts should pay attention to indications of partnerships, technological advancements, or regulatory developments, especially in value-based healthcare, which is increasingly becoming a focal point in oncology.

For investors considering entering or expanding their positions in TOI, readiness for volatility surrounding the earnings release is advisable. Often, preliminary announcements can lead to sharp price movements based on market sentiment. Additionally, leveraging the live call and replay—available for a week post-announcement—can enrich understanding and facilitate informed decision-making.

In summary, the upcoming earnings release is a crucial moment for The Oncology Institute. Stakeholders should be prepared to evaluate the company’s performance against expectations, potential growth trajectories, and the broader implications for its market segment.